• HUGE : NASDAQ • HUGE : CSE  • OK9A : FRA

HUGE on the NASDAQ

FSD is a specialty, biotech pharmaceutical R&D company that aims to deliver growth and returns to shareholders through the development of a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body.

PROCESSING & MANUFACTURING

CANNABINOID

EXTRACTION

PHARMA RESEARCH & DEVELOPMENT

Advancing R&D to fulfill unmet medical needs

FSD’s R&D platform focuses on synthetic compounds that target the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. With the acquisition of Prismic Pharmaceuticals, FSD is also making an effort to help address the opioid crisis by developing opioid-sparing prescription drugs utilizing the micronized formulations of palmitolyethanolamide (PEA). 


The Fundamentals of FSD Pharma are Strong : 


No long term debt





Generated $7.7M proceeds and 670% return on investment through monetizing equity stake in Cannara Biotech


Non-cash assets over $72 M




HUGE NEWS

Discover More about HUGE

Sign Up For Emails

Powered by:

Copyright © 2020. All rights reserved.